



OPEN ACCESS

EDITED BY

Heribert Stoiber,
Innsbruck Medical University, Austria

REVIEWED BY

Kejun Guo,
University of Colorado Anschutz Medical
Campus, United States
Fabio Fiorino,
LUM University Giuseppe Degennaro, Italy
Banuri Gunasekera,
University of Sri Jayewardenepura, Sri
Lanka

*CORRESPONDENCE

Christian A. Devaux
✉ christian.devaux@mediterranee-
infection.com

RECEIVED 03 July 2023

ACCEPTED 28 September 2023

PUBLISHED 10 October 2023

CITATION

Devaux CA and Fantini J (2023) Possible
contribution of rare alleles of human ACE2
in the emergence of SARS-CoV-2 variants
escaping the immune response.
Front. Immunol. 14:1252367.
doi: 10.3389/fimmu.2023.1252367

COPYRIGHT

© 2023 Devaux and Fantini. This is an open-
access article distributed under the terms of
the [Creative Commons Attribution License
\(CC BY\)](https://creativecommons.org/licenses/by/4.0/). The use, distribution or
reproduction in other forums is permitted,
provided the original author(s) and the
copyright owner(s) are credited and that
the original publication in this journal is
cited, in accordance with accepted
academic practice. No use, distribution or
reproduction is permitted which does not
comply with these terms.

Possible contribution of rare alleles of human ACE2 in the emergence of SARS-CoV-2 variants escaping the immune response

Christian A. Devaux^{1,2*} and Jacques Fantini³

¹Institut National des Sciences Biologiques (INSB), Centre National de la Recherche Scientifique (CNRS), Marseille, France, ²Microbes, Evolution, Phylogénie et Infections, Faculté de Pharmacie, Aix Marseille Université, Marseille, France, ³Institut National de la Santé et de la Recherche Médicale (INSERM) U_1072, Faculté des Sciences, Aix-Marseille Université, Marseille, France

Since the start of the SARS-CoV-2 pandemic, the rapid replacement of one lineage by another has been observed. Indeed, SARS-CoV-2 is evolving through a quasispecies mechanism leading to post-infection mutation selection under positive evolutionary pressure (host-driven viral evolution). These mutations may reduce the effectiveness of the specific neutralizing immune response against the virus. We provide here evidence that apart from the selection of SARS-CoV-2 variants by the immune system, selection by the cellular receptor can just as well select variants which escape neutralization.

KEYWORDS

SARS-CoV-2, immune system, selection pressure, ACE2 receptor, genetic drift

Introduction

It has always been considered that the immune response of the host (e.g.; neutralizing antibodies) is a major factor in positive selection of variant viruses (1, 2). In a human population, the encounter with a virus such as SARS-CoV-2 either induces a primary immune response or recalls preexisting memory immune cells specific for each individual histories of infections (3). Although intra-host analysis of SARS-CoV-2 evolution by deep sequencing methods has revealed the existence of one master mutant and numerous minor mutants in quasispecies, minor mutants may obtain a fitness advantage and become the master mutants under high selective pressure, ultimately favoring immune evasion (4). Intra-host genetic diversity was reported for patients treated with monoclonal antibodies targeting the viral spike, this therapeutic use of monoclonal antibodies leading to the selection of SARS-CoV-2 spike protein mutants less susceptible to this therapy. Cases of emergence of SARS-CoV-2 variants with an E₄₈₄K substitution in their spike were reported after Bamlanivimab (5–7) and Bamlanivimab/Etesevimab monoclonal antibodies therapy

(8). Notably, the genetic diversity of SARS-CoV-2 appears to be higher in immunocompromized chronically infected patients. A case report described the genetic evolution of SARS-CoV-2 in a 45-year-old immunocompromized male patient who had received antiviral treatment and anti-spike monoclonal antibodies. During the 151 days the patient had shed SARS-CoV-2, 45 genetic events were observed, including 24 non-synonymous mutations and 34 deletions. Twelve mutations were found in the spike among which substitutions E₄₈₄K and N₅₀₁Y (9). A similar observation was reported for a 59-year-old male patient immunocompromized due to follicular lymphoma and chronically infected with SARS-CoV-2 for 222 days. The authors documented the progressive emergence of viruses with critical spike mutations Q₄₉₃K and N₅₀₁T as majority quasispecies (10). The study of organ-specific intra-sample diversity using tissue samples collected post-mortem in March 2020 from 13 immunocompromized patients died from COVID-19, identified a N₅₀₁Y in the spike of SARS-CoV-2, long before this mutation emerged worldwide (11).

However, another question quickly arose: could not the affinity of the virus for its receptor also play a very important role in the genetic drift of SARS-CoV-2 leading to an immune escape of variant viruses? After electrostatic interactions with lipid rafts (12), the first contact between the virus spike and the host is the virus cellular receptor. Therefore, it is likely that selection pressure impacting viral evolution relates to the virus's affinity for its receptor. In the months following the announcement of the first cases of SARS-CoV-2 in China, angiotensin I converting enzyme 2 (ACE2) was identified as the receptor for this new virus (13). It was subsequently demonstrated that, in addition to serving as attachment receptor to the virus, the ACE2 molecule plays a crucial role in the pathophysiology of COVID-19 (14, 15).

Role of ACE2 in the genetic drift of SARS-CoV-2

Since the World Health Organization declared SARS-CoV-2 to be a pandemic virus, the international community has endeavored to monitor the evolution of these viruses, new variants of which are regularly discovered. This genetic drift of SARS-CoV-2 is associated with the fact that the viral polymerase is error-prone, leading to replacements of SARS-CoV-2 lineages (16). In addition to viral enzyme-driven mutations, there are host parameters such as the apolipoprotein B mRNA editing enzymes (APOBEC) and/or adenosine deaminase acting on RNA (ADAR) systems (17, 18), a selection pressure by the immune system, and resistance factors to viral infections, which contribute to viral genomes evolution (19).

Until recently, the cellular receptor responsible for virus attachment was not considered to contribute to the selection of best-fit viruses in viral quasispecies. It was more generally accepted that the selection pressure exerted on the virus by neutralizing antibodies was responsible for most if not all mutations in the viral spike, and that in some cases these mutations could increase the affinity of the spike for ACE2.

The in-depth study of SARS-CoV-2 sequences circulating in mink advanced the understanding of this complex molecular crosstalk, when it was demonstrated that SARS-CoV-2 present in mink farms had the propensity to evolve by missense mutations, some of which concerned the spike of SARS-CoV-2, such as the Y₄₅₃F mutation (20). Using a structural biology approach, we demonstrated that this host-specific mutation gave a selective advantage to the virus for replication in mink (21). When this virus passes from mink to humans, the mutation is preserved but it is neutral in the binding to human ACE2, inducing neither selective advantage nor an unfavorable effect. SARS-CoV-2 circulating in deer also adapts by mutations that result in viral spikes with F₄₈₆L and N₅₀₁T substitutions that are also host-specific. During the outbreak of SARS-CoV-2 in hamsters, a mutation D₄₂₇G was identified and we demonstrated that it annihilated the torsion that pushes the Q₃₄ amino acid of the hamster ACE2 in unfavorable direction for interaction with the viral spike. This D₄₂₇G substitution could give a selective advantage to this virus to interact with the human ACE2 in case of transmission from hamster to human (22). Altogether, these results indicate that the inter-species polymorphism of ACE2 is an important factor in the selection of new variants.

The pressing question then arose of the role of human ACE2 polymorphism in the emergence of SARS-CoV-2 variants. Thanks to the human genome project, we now know that ACE2 is a polymorphic molecule. Certain alleles more or less frequent dominate in regions of the world and are absent elsewhere (23). Considering the N₅₀₁Y mutation in the spike, we wondered about the existence of ACE2 alleles that could promote its emergence in the human population by intra-specific transmission of the virus. Very recently, we obtained evidence indicating that an N₅₀₁Y variant could be selected when SARS-CoV-2 with an N₅₀₁ was transmitted to people with a rare ACE2 allele (MAF=0.02%) expressing an E₃₂₉G, found in the European human population and absent in Asian people. When hundreds of millions of people are infected, the probability that a SARS-CoV-2 virus will encounter a host that expresses this rare allele is not negligible. Notably, the N₅₀₁Y variant of concern (B.1.1.7), emerged in the UK (24). Very recently, we reported structural evidence that the E₃₂₉G substitution in ACE2 is much more favorable to interaction with the mutated spike protein N₅₀₁Y than it is with E₃₂₉, a physical contact (hydrogen bond) being established between N₅₀₁Y and Q₃₂₅ for ACE2 with E₃₂₉G, whereas this contact does not appear for ACE2 with E₃₂₉ (25).

Discussion

By studying the dynamics of emergence of the N₅₀₁Y lineages of SARS-CoV-2 during the COVID-19 pandemic, we found evidence that a cellular receptor-driven selection process can occur during human-to-human transmission of viruses carrying an asparagine at amino acid position 501 (N₅₀₁) in their spike protein. More precisely, by molecular modeling we demonstrated for the first time, that the encounter of an N₅₀₁ virus with a rare allele of ACE2 (E₃₂₉G) could lead to the

selection of an N₅₀₁Y lineage SARS-CoV-2 viruses exhibiting higher affinity for the receptor (25) and lower susceptibility to neutralization by antibodies (26, 27).

Of course, we have no formal proof that the history of the emergence of N₅₀₁Y viruses occurred through ACE2 rare allele selection in humans. Alongside the selective advantage provided by the N₅₀₁Y substitution for the replication of SARS-CoV-2 in humans, we know that N₅₀₁Y also gives a selective advantage to the virus for replication in mink, mice and deer which could also have contributed to the emergence of such a variant through inter-species transmission (e.g., there are Q or G, Q, and D amino acids in place of the E at position 329 in the ACE2 sequences of hamster, mice, and deer, respectively). However, the model of virus evolution by selection in a human host expressing a rare ACE2 allele (Figure 1), followed by a boomerang effect in the general population, remains a very attractive hypothesis. In the study by Van cleemput and colleagues (11), it would have been interesting to know the ACE2 allele carried by the immunocompromized patients whose viruses, found in samples from March 2020, carry the N₅₀₁Y mutation in their spike. Since the Alpha (B1.1.7; first detection was in November 2020 in UK), Beta (B.1.351; first detection was in October 2020 in South Africa) and Gamma (P.1; first detection was in January 2021 in Japan) variants of SARS-CoV-2 that carried this N₅₀₁Y substitutions appeared during late 2020 and early 2021, it remains possible that the N₅₀₁Y lineage first emerged in an immunocompromized male patient infected

with SARS-CoV-2 who expressed a rare allele of ACE2. The fact that the ACE2 gene is on chromosome X (28, 29) supports this hypothesis. However, more than three years after its emergence, it would be extremely complex to attempt to trace back the hypothetical origin of the N₅₀₁Y variant of concern in a population expressing the rare allele E₃₂₉G of ACE2 in the UK, by direct genotyping. As suggested by a reviewer of this paper, an elegant way to approach the problem today might be to carry out an *in vitro* experiment of serial passages of an ancestral SARS-CoV-2 that does not contain the N₅₀₁Y in a compatible cell line expressing an ACE2 with E₃₂₉G substitution in order to observe the possible emergence of a N₅₀₁Y variant. We are not discussing it in this short communication, but the N₅₀₁Y variant of concern could also have been selected for adaptation to another receptor or co-receptors (e.g., NRP-1) (30), in different tissues and organs in humans (which could also be regarded as an example of host receptor-driven virus mutation). If the virus receptor expressed by the host can play a selection role in the same way as the immune system, in an immunocompromized patient the role of the receptor can theoretically become preponderant. Moreover, this model of virus selection by adaptation to the receptor could be interesting to explore for other mutations that affect the Spike protein of SARS-CoV-2.

Finally, although the accumulation of whole genome sequences with SARS-CoV-2 has made it possible to observe these rare events, it is likely that this selection mechanism may exist for other viruses and their respective receptors. This opens




FIGURE 1
Hypothetical model of immune escape by selection pressure at the level of the viral receptor. This model proposes the intervention of an individual expressing a rare allele of ACE2 (E₃₂₉G) in the selection of the N₅₀₁Y lineage of SARS-CoV-2 then its transmission to human populations expressing the major ACE2 (E₃₂₉) allele. In this model, three main forces act on the genetic drift of the virus: the fitness capacity of the virus, the sequence of the host's ACE2 serving as a receptor for the virus and, the host's anti-SARS-CoV-2 immune response. For more detail on the genetic drift of the virus see reference (17) and reference (18) for the immune response aspect. Please refer to the main text and reference (25) for descriptions of variants of concern.

up an avenue for the exploration of a new mechanism of virus evolution. It is time to take into account both the selection pressure of the immune system and that imposed by the cellular receptors of viruses in their genetic drift.

Data availability statement

The original contributions presented in the study are included in the article/supplementary materials. Further inquiries can be directed to the corresponding author.

Author contributions

All authors listed have made a substantial, direct, and intellectual contribution to the work and approved it for publication. All authors contributed to the article and approved the submitted version.

Funding

This work was supported by the French Government under the “Investissements d’avenir” (Investments for the Future) program

References

- Chang MR, Ke H, Coherd CD, Wang Y, Mashima K, Kastrunes GM, et al. Analysis of a SARS-CoV-2 convalescent cohort identified a common strategy for escape of vaccine-induced anti-RBD antibodies by Beta and Omicron variants. *eBioMedicine* (2023) 80:104025. doi: 10.1016/j.ebiom.2022.104025
- Chen Y, Zhao X, Zhou H, Zhu H, Jiang S, Wang P. Broadly neutralizing antibodies to SARS-CoV-2 and other human coronaviruses. *Nat Rev Immunol* (2023) 23:189–99. doi: 10.1038/s41577-022-00784-3
- Devaux CA, Fantini J. Unravelling antigenic cross-reactions toward the world of coronaviruses: extent of the stability of shared epitopes and SARS-CoV-2 anti-spike cross-neutralizing antibodies. *Pathogens* (2023) 12:713. doi: 10.3390/pathogens12050713
- Dudouet P, Colson P, Aherfi S, Levasseur A, Beye M, Delerce J, et al. SARS-CoV-2 quasi species analysis from patients with persistent nasopharyngeal shedding. *Sci Rep* (2022) 12:18721. doi: 10.1038/s41598-022-22060-z
- Peiffer-Smadja N, Bridier-Nahmias A, Ferré VM, Charpentier C, Garé M, Rioux C, et al. Emergence of E484K mutation following bamlanivimab monotherapy among high-risk patients infected with the alpha variant of SARS-CoV-2. *Viruses* (2021) 13(8):1642. doi: 10.3390/v13081642
- Jensen B, Luecke N, Feldt T, Keitel V, Brandenburger T, Kindgen-Milles D, et al. Emergence of the E484K mutation in SARS-CoV-2-infected immunocompromised patients treated with bamlanivimab in Germany. *Lancet Reg Health Eur* (2021) 8:100164. doi: 10.1016/j.lanpe.2021.100164
- Lohr B, Niemann D, Verheyen J. Bamlanivimab treatment leads to rapid selection of immune escape variant carrying the E484K mutation in a B.1.1.7-infected and immunosuppressed patient. *Clin Infect Dis* (2021) 73(11):2144–5. doi: 10.1093/cid/ciab392
- Vellas C, Del Bello A, Debarb A, Steinmeyer Z, Tribaudeau L, Ranger N, et al. Influence of treatment with neutralizing monoclonal antibodies on the SARS-CoV-2 nasopharyngeal load and quasispecies. *Clin Microbiol Infect* (2022) 28(1):139.e5–8. doi: 10.1016/j.cmi.2021.09.008
- Choi B, Choudhary MC, Regan J, Sparks JA, Padera RF, Qiu X, et al. Persistence and evolution of SARS-CoV-2 in an immunocompromised host. *N Engl J Med* (2020) 383(23):2291–3. doi: 10.1056/NEJMc2031364
- Caccuri F, Messali S, Bortolotti D, Di Silvestre D, De Palma A, Cattaneo C, et al. Competition for dominance within replicating quasispecies during prolonged SARS-

managed by the Agence Nationale de la Recherche (ANR, FR: National Agency for Research), (reference: Méditerranée Infection 10-IAHU-03) and an annual budget allocation from the Aix-Marseille University and the “Institut de Recherche pour le Développement” (IRD) to the Microbes Evolution Phylogeny and Infection (MEPHI) laboratory.

Conflict of interest

CD owns shares in the Sanofi and Merck pharmaceutical companies.

The remaining author declares that the research was conducted in the absence of any commercial or financial relationships that could be constructed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

- CoV-2 infection in an immunocompromised host. *Virus Evol* (2022) 8(1):veac042. doi: 10.1093/ve/veac042
- Van Cleemput J, van Snippenberg W, Lambrechts L, Dendooven A, D’Onofrio V, Couck L, et al. Organ-specific genome diversity of replication-competent SARS-CoV-2. *Nat Commun* (2021) 12(1):6612. doi: 10.1038/s41467-021-26884-7
 - Fantini J, Azzaz F, Chahimian H, Yahi N. Electrostatic surface potential as a key parameter in virus transmission and evolution: how to manage future virus pandemics in the post-COVID-19 era. *Viruses* (2023) 15(2):284. doi: 10.3390/v15020284
 - Zhou P, Yang X, Wang XG, Hu B, Zhang L, Zhang W, et al. A pneumonia outbreak associated with a new coronavirus of probable bat origin. *Nature* (2020) 579(7798):270–3. doi: 10.1038/s41586-020-2012-7
 - Zoufaly A, Poglitsch M, Aberle JH, Hoepler W, Seitz T, Traugott M, et al. Human recombinant soluble ACE2 in severe COVID-19. *Lancet Respir Med* (2020) 8:1154–8. doi: 10.1016/S2213-2600(20)30418-5
 - Osman IO, Melenotte C, Brouqui P, Million M, Lagier J-C, Parola P, et al. Expression of ACE2, soluble ACE2, angiotensin I, angiotensin II and angiotensin-(1-7) is modulated in COVID-19 patients. *Front Immunol* (2021) 12:625732. doi: 10.3389/fimmu.2021.625732
 - Carabelli AM, Peacock TP, Thorne LG, Harvey WT, Hughes J. COVID-19 Genomics UK Consortium, et al. SARS-CoV-2 variant biology: immune escape, transmission and fitness. *Nat Rev Microbiol* (2023) 21:162–77. doi: 10.1038/s41579-021-00573-0
 - Pecori P, Di Giorgio S, Paulo Lorenzo J, Papavasiliou FN. Functions and consequences of AID/APOBEC-mediated DNA and RNA deamination. *Nat Rev Genet* (2022) 23:505–18. doi: 10.1038/s41576-022-00459-8
 - Ringlander J, Fingal J, Kann H, Prakash K, Rydell G, Andersson M, et al. Impact of ADAR-induced editing of minor viral RNA populations on replication and transmission of SARS-CoV-2. *Proc Natl Acad Sci USA* (2022) 119(6):e2112663119. doi: 10.1073/pnas.2112663119
 - Yue C, Song W, Wang L, Jian F, Chen X, Gao F, et al. ACE2 binding and antibody evasion in enhanced transmissibility of XBB.1.5. *Lancet Infect Dis* (2023) 23:278–80. doi: 10.1016/S1473-3099(23)00010-5
 - Oude Munnink BB, Sikkema RS, Nieuwenhuijse DF, Jan Molenaar R, Munger E, Molenkamp R, et al. Transmission of SARS-CoV-2 on mink farms between humans and mink and back to humans. *Science* (2021) 371:172–7. doi: 10.1126/science.abe5901

21. Frutos R, Yahi N, Gavotte L, Fantini J, Devaux CA. Role of spike compensatory mutations in the interspecies transmission of SARS-CoV-2. *One Health* (2022) 15:100429. doi: 10.1016/j.onehlt.2022.100429
22. Fantini J, Devaux CA, Yahi N, Frutos R. The novel hamster-adapted SARS-CoV-2 Delta variant may be selectively advantaged in humans. *J Infect* (2022) 84:e53–4. doi: 10.1016/j.jinf.2022.03.001
23. Cao Y, Li L, Feng Z, Wan S, Huang P, Sun X, et al. Comparative genetic analysis of the novel coronavirus (2019-nCoV/SARS-CoV-2) receptor ACE2 in different populations. *Cell Discovery* (2020) 6:4–7. doi: 10.1038/s41421-020-0147-1
24. Leung K, Shum MHH, Leung GM, Lam TT, Wu JT. Early transmissibility assessment of the N501Y mutant strains of SARS-CoV-2 in the United Kingdom, October to November 2020. *Eurosurveillance* (2021) 26(1):2002106. doi: 10.2807/1560-7917.ES.2020.26.1.2002106
25. Devaux CA, Fantini J. ACE2 receptor polymorphism in humans and animals increases the risk of the emergence of SARS-CoV-2 variants during repeated intra and inter-species host-switching of the virus. *Front Microbiol* (2023) 14:1199561. doi: 10.3389/fmicb.2023.1199561
26. Martin DP, Weaver S, Tegally H, San JE, Shank SD, Wilkinson E, et al. The emergence and ongoing convergent evolution of the SARS-CoV-2 N501Y lineages. *Cell* (2021) 184:5189–200. doi: 10.1016/j.cell.2021.09.003
27. Uzoeto HO, Ajima JN, Arazu AV, Ibiang GO, Cosmas S, Durojaye OA, et al. Immunity evasion: consequence of the N501Y mutation of the SARS-CoV-2 J. *Genet Eng Biotechnol* (2022) 20(1):10. doi: 10.1186/s43141-021-00287-Z
28. Turner AJ, Hooper NM. The angiotensin-converting enzyme gene family: genomics and pharmacology. *Trends Pharmacol Sci* (2002) 23:177–83. doi: 10.1016/s0165-6147(00)01994-5
29. Devaux CA, Camoin-Jau L. An update on angiotensin-converting enzyme 2 structure/functions, polymorphism, and duplicitous nature in the pathophysiology of coronavirus disease 2019: Implications for vascular and coagulation disease associated with severe acute respiratory syndrome coronavirus infection. *Front Microbiol* (2022) 13:1042200. doi: 10.3389/fmicb.2022.1042200
30. Cantuti-Castelvetri L, Ojha R, Pedro LD, Djannatian M, Franz J, Kuivanen S, et al. Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity. *Science* (2020) 370:856–60. doi: 10.1126/science.abd2985